Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.
10.3350/cmh.2015.21.4.344
- Author:
Hyun Young WOO
1
;
Jeong HEO
Author Information
1. Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, Korea. jheo@pusan.ac.kr
- Publication Type:Research Support, Non-U.S. Gov't ; Review
- Keywords:
Drug eluting beads;
Hepatocellular carcinoma;
Transarterial chemoembolization
- MeSH:
Antineoplastic Agents/administration & dosage/chemistry;
Carcinoma, Hepatocellular/*therapy;
Chemoembolization, Therapeutic;
Drug-Eluting Stents;
Ethiodized Oil/chemistry;
Humans;
Liver Neoplasms/*therapy
- From:Clinical and Molecular Hepatology
2015;21(4):344-348
- CountryRepublic of Korea
- Language:English
-
Abstract:
Transarterial chemoembolization (TACE) using doxorubicin-eluting beads (DEBs) have been introduced as a novel device which ensures more sustained and tumor-selective drug delivery and permanent embolization compared to conventional TACE with lipiodol. Studies highlighting the use of TACE with DEBs for the treatment of hepatocellular carcinoma (HCC) have shown similar or better results compared to conventional TACE with lipiodol. TACE with DEBs is increasingly being performed interchangeably with conventional TACE. This review assessed the characteristics, clinical outcomes and future direction of TACE with DEBs compared to conventional TACE.
